NCT06548945View on ClinicalTrials.gov

A Phase I Study of GZR18 Injection in Obese/Overweight Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 25, 2023

Primary Completion Date

August 14, 2023

Study Completion Date

August 14, 2023

Conditions
Overweight and Obesity
Interventions
DRUG

GZR18

5 mg-maximum tolerated dose (MTD), single dose

OTHER

Placebo

administered the same volume as GZR18

Trial Locations (1)

Unknown

Gan & Lee Pharmaceuticals Co., Ltd, Beijing

Sponsors
All Listed Sponsors
lead

Gan and Lee Pharmaceuticals, USA

INDUSTRY